Study shows no progressive increase of MRI structural lesions in SI joints of health individuals with increasing age, including: Bone marrow edema, erosions, fat lesions Abs#2258 @RheumNow #ACR22 https://t.co/W2dkRCAPc4

SSc and DM/PM can cause disease related sexual dysfunction ➡️ consider pelvic floor PT Abstract #0940 #ACR22 @RheumNow 🧘‍♀️8 week PT program targeting pelvic floor exercises and MSK issues impacting sexual function 🧘Women experienced sig. improved sexual function and QOL

Ab1677 #ACR22 by @MaxKonigMD Chimeric autoAg T cell recepter (CATCR) reprogram T cells to selectively kill autoreactive B cells Model CATCR for APLS via B2GPI-CATCR T-cells eliminating anti-B2GP DI B cells, dose-dependent Model for SELECTIVE Rx in APLS/rheum disease @RheumNow https://t.co/jMpMu10phL

Very cool preclinical plenary @MaxKonigMD Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells) Early days but super interesting possibilities - APS, SLE, AAV, & more? #ACR22 @rheumnow #ACRBest Abstr#1677 https://t.co/nS3YtR6wN9

#ACR22 highlights. #PMR May have Steroid sparing options. #tocilizumab abst#1106, #tofacitinib abst1107, #sarilumab #1676. Also previous #secukinumab ALL positive RCTs #ACRBest @RheumNow

Izmirly et al. HCQ crosses placenta but no evidence ocular toxicity in children at 5 years old by OCT @RheumNow #ACR22 Abstr#1674 https://t.co/yMQzt6sU7i

• In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity…

Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies: precision cellular therapy selectively deplete autoreactive B cells @MaxKonigMD in the plenary: CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells #ACR22 @RheumNow https://t.co/5ZLocrwqKY

GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently. @RheumNow #ACR22 #Plenary

#ACR22 Highlights. ILD in CTDs #rituximab = #cyclophoshamide at 6 mo for CTD ILD & ritux better on skin score in #scleroderma RECITAL RCT abst0003 but #pirfenidone added to #MMF not better than MMF alone in SLSIII RCT—ILD w #SSc abst#520 vs in SENCIS #nintedanib is + @RheumNow

Great moderating PMR talk w/@SattuiSEMD this AM; phenomenal slides @drceowen re:imaging in PMR Big ?s: -Who needs this? All/some/many -Which modality? Nice summary slide -How to treat "subclinical" GCA (risk of overtreatment imo) Ideas for next year? #ACR22 @rheumnow #ACRBest https://t.co/akvsud3YVO

Preterm delivery and HTN disorders in #vasculitis Abstract #0953 #ACR22 @RheumNow @StanfordRheum 🤰87 deliveries from 1991-2012 🤰Higher risk for preterm delivery (PTD) (RR 4), PPROM (RR 4), HTN dx of preg. (RR 3) 🤰Of spon. PTD, 17% born between 20-31 weeks

Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology? #ACR22 https://t.co/TThsEQ7RDH https://t.co/ZHNlH3J0de

• https://bit.ly/3Adf2KM

Ab1676 #ACR22 SAPHYR: Sarilumab in Refractory PMR 52wk SAR 200 mg q2w + 14w taper GC v PBO+GC taper Primary endpt: sustain response at 52w Early term 2/2 COVID, 117 pt SAR remission 28% vs PBO 10%, p=0.02 Data consistent when removes CRP data PBO: more GCs 2/2 PMR flare @Rheumnow https://t.co/kHq3juULX1

How much does diet and exercise help in knee osteoarthritis? Pragmatic RCT (WE-CAN), n=823 a diet & exercise intervention program led to: - 10kg weight loss - some significant pain improvements We need to fund diet & exercise programs for OA patients! ABST1675 #ACR22 @RheumNow https://t.co/Ctm8ZoRF3o

Update on ACR Guideline on Prevention and Treatment of GIOP. Sequential Rx when initial OP Rx and GC discontinued https://t.co/TWdI728pCp Mary Beth Humphrey #ACR22 @RheumNow https://t.co/i320si4RJp

• http://bit.ly/3hFVMzc